Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach
The orphan G protein coupled receptor 6 (GPR6) is a cannabinoid-related Class A GPCR. It is highly expressed in the central nervous system and exhibits high constitutive activation of adenylyl cyclase. Several research groups have demonstrated that GPR6 represents a possible target for the treatment...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Proceedings |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2504-3900/22/1/29 |
| _version_ | 1827092850555224064 |
|---|---|
| author | Israa Isawi Paula Morales Dow Hurst Nadine Jagerovic Patricia Reggio |
| author_facet | Israa Isawi Paula Morales Dow Hurst Nadine Jagerovic Patricia Reggio |
| author_sort | Israa Isawi |
| collection | DOAJ |
| description | The orphan G protein coupled receptor 6 (GPR6) is a cannabinoid-related Class A GPCR. It is highly expressed in the central nervous system and exhibits high constitutive activation of adenylyl cyclase. Several research groups have demonstrated that GPR6 represents a possible target for the treatment of neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases. Several patents claim the use of a wide range of pyrazine derivatives as GPR6 inverse agonists for the treatment of Parkinson’s disease and other dyskinesia syndromes. Using cyclic AMP accumulation assays in <i>h</i>GPR6-CHO cells as a readout, the most potent GPR6 pyridopyrazine inverse agonist compounds identified thus far have been found to display IC<sub>50</sub> values in the low nanomolar range. A subset of these compounds was used here as starting points for the design of novel potent GPR6 inverse agonists using a core hopping approach. In parallel with the core hopping studies, we employed a recently constructed homology model of the GPR6 inactive state. The X-ray crystal structure of the Sphingosine-1-phosphate receptor 1 (S1P1) receptor structure was used as the template and the conformational memories technique was used to explore the conformational consequences of sequence differences between S1P1 and GPR6. The most potent GPR6 pyridopyrazine inverse agonists were docked in the resultant GPR6 inactive state model, first as tests of the model. Once we had identified the binding site of each inverse agonist, we used this site to identify amino acid sites in proximity that we can use to build additional interactions for ligands output from core hopping studies above. ADME properties and the absence of PAINS will also be considered for the hit selection process. These potential GPR6 chemotypes may serve as research tools for further understanding the biological role of this orphan receptor. |
| first_indexed | 2024-04-13T00:15:16Z |
| format | Article |
| id | doaj.art-ee178a2bce784273b024a486c58a2acc |
| institution | Directory Open Access Journal |
| issn | 2504-3900 |
| language | English |
| last_indexed | 2025-03-20T06:18:45Z |
| publishDate | 2019-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proceedings |
| spelling | doaj.art-ee178a2bce784273b024a486c58a2acc2024-10-02T16:20:16ZengMDPI AGProceedings2504-39002019-08-012212910.3390/proceedings2019022029proceedings2019022029Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping ApproachIsraa Isawi0Paula Morales1Dow Hurst2Nadine Jagerovic3Patricia Reggio4Chemistry & Biochemistry Dept., UNCG, Greensboro, NC 27412, USAInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, E-28006 Madrid, SpainChemistry & Biochemistry Dept., UNCG, Greensboro, NC 27412, USAInstituto de Química Médica, Consejo Superior de Investigaciones Científicas, E-28006 Madrid, SpainChemistry & Biochemistry Dept., UNCG, Greensboro, NC 27412, USAThe orphan G protein coupled receptor 6 (GPR6) is a cannabinoid-related Class A GPCR. It is highly expressed in the central nervous system and exhibits high constitutive activation of adenylyl cyclase. Several research groups have demonstrated that GPR6 represents a possible target for the treatment of neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases. Several patents claim the use of a wide range of pyrazine derivatives as GPR6 inverse agonists for the treatment of Parkinson’s disease and other dyskinesia syndromes. Using cyclic AMP accumulation assays in <i>h</i>GPR6-CHO cells as a readout, the most potent GPR6 pyridopyrazine inverse agonist compounds identified thus far have been found to display IC<sub>50</sub> values in the low nanomolar range. A subset of these compounds was used here as starting points for the design of novel potent GPR6 inverse agonists using a core hopping approach. In parallel with the core hopping studies, we employed a recently constructed homology model of the GPR6 inactive state. The X-ray crystal structure of the Sphingosine-1-phosphate receptor 1 (S1P1) receptor structure was used as the template and the conformational memories technique was used to explore the conformational consequences of sequence differences between S1P1 and GPR6. The most potent GPR6 pyridopyrazine inverse agonists were docked in the resultant GPR6 inactive state model, first as tests of the model. Once we had identified the binding site of each inverse agonist, we used this site to identify amino acid sites in proximity that we can use to build additional interactions for ligands output from core hopping studies above. ADME properties and the absence of PAINS will also be considered for the hit selection process. These potential GPR6 chemotypes may serve as research tools for further understanding the biological role of this orphan receptor.https://www.mdpi.com/2504-3900/22/1/29GPR6Scaffold HoppingParkinson’s Disease |
| spellingShingle | Israa Isawi Paula Morales Dow Hurst Nadine Jagerovic Patricia Reggio Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach Proceedings GPR6 Scaffold Hopping Parkinson’s Disease |
| title | Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach |
| title_full | Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach |
| title_fullStr | Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach |
| title_full_unstemmed | Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach |
| title_short | Design of Novel GPR6 Inverse Agonists Using a Fragment Replacement Scaffold Hopping Approach |
| title_sort | design of novel gpr6 inverse agonists using a fragment replacement scaffold hopping approach |
| topic | GPR6 Scaffold Hopping Parkinson’s Disease |
| url | https://www.mdpi.com/2504-3900/22/1/29 |
| work_keys_str_mv | AT israaisawi designofnovelgpr6inverseagonistsusingafragmentreplacementscaffoldhoppingapproach AT paulamorales designofnovelgpr6inverseagonistsusingafragmentreplacementscaffoldhoppingapproach AT dowhurst designofnovelgpr6inverseagonistsusingafragmentreplacementscaffoldhoppingapproach AT nadinejagerovic designofnovelgpr6inverseagonistsusingafragmentreplacementscaffoldhoppingapproach AT patriciareggio designofnovelgpr6inverseagonistsusingafragmentreplacementscaffoldhoppingapproach |